数据治理平台产品研发

Search documents
股市必读:创业慧康(300451)7月23日董秘有最新回复
Sou Hu Cai Jing· 2025-07-23 19:32
Core Viewpoint - The company, Chuangye Huikang, is focusing on innovation in the healthcare information technology sector, with significant investments in research and development aimed at enhancing its product offerings and operational efficiency [2][3]. Group 1: Company Performance - As of July 23, 2025, Chuangye Huikang's stock closed at 5.55 yuan, down 1.07%, with a turnover rate of 2.56%, a trading volume of 391,400 shares, and a transaction value of 219 million yuan [1]. - On the same day, the net outflow of funds from major investors was 18.81 million yuan, while retail investors saw a net inflow of 20.50 million yuan [4]. Group 2: Research and Development Focus - The company reported that its R&D investment accounted for 20-30% of its revenue, focusing on areas such as smart healthcare, regional health, and health city development [2]. - Key projects include the Hi-HIS clinical medical system, integrated grassroots health information systems, and a data governance platform [2]. - The company is actively integrating artificial intelligence into its operations, with products like Smart EMR and My Doctor being deployed in medical settings [2]. Group 3: Strategic Initiatives - The "Huikang Cloud" transformation strategy initiated in 2021 aims to migrate management and collaboration processes to the cloud, enhancing operational efficiency and resource sharing [2]. - The company is upgrading its low-code platform to reduce development complexity and implementation time for its core products, thereby improving the maturity and functionality of its Hi-HIS offerings [2].